

Eosinopenia and Neutrophil to Lymphocyte Ratio in COVID-19 Infection, a Prospective Study from Tertiary Care Hospital in Pakistan

Syed Muhammad Kashif¹, Wish Hal Sunder¹, Rashid Qadeer¹, Darshan Kumar¹, Gul Anum^{1*}, Ravi Kumar²

ABSTRACT

OBJECTIVE: To assess eosinopenia and neutrophil to lymphocyte ratio in patients admitted with COVID-19 infection and correlate with pneumonia severity.

METHODOLOGY: This prospective observational study was conducted at Covid HDU of Dr. Ruth KM Pfau Civil Hospital, Karachi, from October - December 2021. Data was collected using convenience sampling. The inclusion criteria were patients between 18-70 years with symptoms suggestive of COVID-19 and positive RT-PCR. Patients with negative RT-PCR with alternate diagnosis, history of using a corticosteroid, pancreatic or esophageal malignancy, and recent burn were excluded. Data analysis was done using SPSS version 23.

RESULTS: Out of 141 patients, 66(46%) were classified as non-severe covid and 75(53.9%) as severe covid pneumonia. A significant association between eosinopenia and COVID severity was observed. The NLR was significantly increased in severe COVID patients compared to non-severe patients. Similarly, eosinophil was decreased considerably in severe covid compared to non-severe patients (p -value<0.05). The area under the eosinopenia ROC curve is 0.71 and 0.69 on days 7 and 3, respectively. Thus, eosinopenia on day 7 was fair in predicting severe COVID-19 pneumonia compared with increased NLR, which was poor in predicting severe COVID-19. Using the area under the ROC curve, an eosinophil count cutoff of <100 cells/mm³ produced a sensitivity of 75% for severe COVID-19 pneumonia.

CONCLUSION: Eosinopenia and elevated NLR were found with increased frequency in patients with severe COVID-19 pneumonia; however, persistent eosinopenia was a better marker than NLR in predicting COVID-19 infection severity.

KEYWORDS: Eosinopenia, Neutrophil to lymphocyte ratio, Covid-19, Pneumonia.

INTRODUCTION

NLR is the ratio used to assess subclinical inflammation and is measured by dividing the neutrophils by the number of lymphocytes while measuring the complete blood count. A higher NLR is a predictor of cardiovascular events and all-cause death¹. The NLR can be used in many clinical scenarios as a prognostic marker, and presently, the NLR ratio is significantly observed as a prognostic marker in patients admitted with COVID-19 infection in which a significant difference in the NLR ratio is found in recovered and dead patients². The NLR ratio is 0.78 to 3.53 in 95% of healthy adult subjects³.

Eosinopenia is a form of granulocytopenia with lower counts than expected. Eosinopenia with leukocytosis is the predictor of bacterial infection, while eosinopenia with lymphopenia is observed as a

marker to assess the severity in patients with COVID-19 infection^{4,5}. Increased absolute neutrophil count with leukocytosis is found in severely ill patients of COVID-19 and is a separate risk factor for inpatient death⁶.

Eosinopenia $<0.02 \times 10^9$ cells/L was found in more than half of the admitted patients on admission⁷. It is observed that eosinopenia had high sensitivity and specificity in diagnosing COVID-19 infection, and the eosinophil/PMN ratio is a helpful measure for COVID-19 diagnosis⁸. A study by Roser Terradas found the significance of Eosinopenia (0.0454×10^3 /ul) and NLR ratio > 7 as poor prognostic indicators in bacteremia patients. Survivors in this study tended to raise eosinophil count and reduce NLR <7 on days 2 and 3 of admission⁹. Eosinophil-related ratios were also found as markers of survival in patients with endometrial carcinoma¹⁰. Eosinophil to lymphocyte ratio is also observed in many hypersensitivity reactions to NSAIDs¹¹. SARS-CoV-2 infection is found to alter many blood parameters, which have prognostic significance, and their timely assessment helps in better management. Severe COVID-19 infection is observed by marked eosinopenia, and higher NLR has been seen in patients known to have diabetes and hypertension¹². Eosinopenia and raised

¹Department of Medicine, Dr. Ruth K. M. Pfau Civil Hospital, Dow University of Health Sciences, Karachi, Sindh-Pakistan

²Department of Medicine, Altamash Institute of Dental Medicine, Karachi, Sindh-Pakistan

*Correspondence: arian4gul@gmail.com

doi: 10.22442/jlumhs.2023.01008

Received: 28-12-2022

Revised: 24-08-2023

Accepted: 30-08-2023

Published Online: 08-11-2023



NLR are essential tools to diagnose COVID-19 infection in patients having symptoms suggestive of COVID-19 even with negative PCR. A study by Vasiliki E Georgakopoulou found statistically significant eosinopenia and eosinophil to lymphocyte count in patients admitted with moderate to severe COVID-19¹³.

Eosinopenia and NLR are efficient and effective measures in diagnosing and evaluating the severity and have prognostic significance. This study assesses the eosinopenia and NLR in patients admitted with SARS-CoV-2 infection and correlates them with the severity of pneumonia and length of hospital stay.

METHODOLOGY

This observational prospective study was conducted at medical units 1 and 5, designated as Covid HDU of Dr. Ruth KM Pfau, Civil Hospital Karachi, from October - December 2021 with a convenience sampling technique. This study was reviewed and accepted by the institutional review board committee of Dow University of Health Sciences.

Using the reported prevalence of COVID-19 diseases in different phases, it was found that between 8.5% and 15% of the population of Karachi were affected. A sample size of 140 achieves 80% power to detect a 95% confidence interval and an odd ratio of 4 with a prevalence ratio of 3.5 and a prevalence difference of 12. The sample size was calculated using openEPI.

Inclusion Criteria

- All patients are between 18-70 years.
- Patients with symptoms suggestive of COVID-19 and positive RT-PCR SARS-CoV-2.
- Negative SARS-CoV-2 detection by RT-PCR but having prominent features such as clinical, biochemical, and radiological evidence supporting SARSCoV-2.

Exclusion Criteria

- Negative RT-PCR SARS-CoV-2 with alternate diagnosis, history of using corticosteroid.
- Exacerbation of COPD, pancreatic cancer, esophageal cancer, Cushing's syndrome, history of recent burn, and stress inducer

All patients between 18 and 70 years who presented to the emergency room with suspected symptoms suggestive of COVID-19 were included. Symptoms favouring COVID-19 include unexplained fever of >38 °C, flu-like symptoms, cough, shortness of breath, loose motion in those older than 65, and a history of exposure to infected patients⁸.

All the participants who were admitted to the COVID-19 treatment centre with positive covid-19 detection by RT-PCR, or in case negative covid-19 detection by RT-PCR but having prominent features such as clinical, biochemical, and radiological evidence supporting SARS-CoV-2 were included in the study after taking proper consent.

Before the study started, permission from the ethical committee was requested. Patients received adequate

information regarding the study, and patient confidentiality was upheld. Each patient's demographics, brief history, clinical examinations, and comorbidities, like DM and HTN, were documented on proforma.

PCR for RNA COVID-19 virus was done through a nasopharyngeal swab. CBC, CRP, LDH, ferritin, D-DIMER, TSH, procalcitonin, LFT, PT/INR, and chest x-rays were done at the time of admission and during a stay in the hospital. The complete blood count of all patients included the no. of eosinophils, lymphocytes, PMN (with the calculation of neutrophil to lymphocyte ratio × 1000), platelets, and the haemoglobin (Hb) concentration. Repeated labs were done on days 1, 3, and 7 to compare biochemical parameters with patients' conditions and radiology.

Patients were categorized as non-severe and severe COVID pneumonia according to the clinical management guidelines issued by the Ministry of National Health Services, Govt of Pakistan.

Descriptive data were collected as frequencies and percentages, using mean and median values for variables such as differential white cell counts, frequencies of the gender, and comorbidities like DM and HTN, which will be reported and compared with gender by Student's t-test. Means ±SD will be reported for age and COVID-19 severity assessed. Using the chi-square test and independent t-test, baseline demographic, clinical, and laboratory data were compared between disease severity categories. Each haematological parameter was compared with various severity groups using one-way analysis of variance (ANOVA) as the statistical significance test. P-value 0.05 was the threshold for statistical significance. All tests for hypotheses had two tails. The analysis was done with the help of SPSS software version 23.0. COVID-19 severity and the results were categorized as per the outcome achieved.

RESULTS

A total of 141 patients were included in our study. Out of 141 patients, 65(46%) were males and 76(53.9%) were females. 66(46.8%) patients were classified as non-severe covid and 75(53.1%) were classified as severe covid. In our study, the mean age of the non-severe covid patients was 39 years, whereas that of severe covid patients was 46 years. The most common symptom in the non-severe COVID group was abdominal pain, loose stool, and vomiting. In contrast, respiratory symptoms, i.e., dry cough and dyspnea, were significantly more present in the severe cohort, as shown in **Table I**. Table I shows the clinical characteristics of our sample. According to **Table II**, the haematological parameters between the two cohorts were compared. The NLR on Days 1, 3 and 7 was significantly increased in severe covid patients compared to non-severe patients (10.9 vs 7.3 p-values = 0.002), (11.7 vs 6.3 p-values = <0.001), (11.8 vs 6.1 p-values = 0.009) respectively. Similarly,

Table I: Baseline Clinical Features Comorbid illness and vital characteristics of COVID-19 patients concerning disease severity

Disease severity Statistic	Non-severe (n =66)		Severe (n =75)		Pearson Chi-Square	
	n	%	n	%	Value	P-value
Age (years) mean±SD	39±7.39		46.9±12.34			
Gender					0.284	0.594
Male	32	49.2	33	50.8		
Female	34	44.7	42	55.3		
Clinical features						
Abdominal pain	27	64.3%	15	35.7%	7.339	0.007
Vomiting	27	61.4%	17	38.6%	5.442	0.020
Diarrhea	18	62.1%	11	37.9%	3.415	0.065
Fever	56	45.5%	67	54.5%	0.634	0.426
Dry cough	36	38.7%	57	61.3%	7.197	0.007
Loose motions	20	69.0%	9	31.0%	7.199	0.007
Dyspnea	34	35.4%	62	64.6%	15.678	<0.001
Comorbid illness						
HTN	27	51.9%	25	48.1%	0.866	0.352
DM	23	46.9%	26	53.1%	0.001	0.982
CLD	8	66.7%	4	33.3%	2.077	0.149
COPD	27	51.9%	25	48.1%	0.866	0.352
CVD	23	46.9%	26	53.1%	0.001	0.982
HIV	8	66.7%	4	33.3%	2.077	0.149
Vitals						
Systolic (mmHg)	122.6818	15.17605	124.8400	14.07993	-0.876	0.383
Diastolic (mmHg)	76.4848	10.80063	78.5600	9.66079	-1.204	0.231
Pulse (beats/minute)	85.0000	10.01998	81.8267	10.54126	1.825	0.070
PaCO2	35.7348	8.38663	38.3840	7.71440	-1.953	0.053

Table II: Laboratory parameters of COVID-19 patients concerning Disease Severity

Disease severity Statistic	Non-severe (n =66)		Severe (n =75)		Independent Samples Test	
	Mean	SD	Mean	SD	Value	P-value
Hematological markers						
HbA1C	5.63	1.15	5.84	1.34967	-0.941	0.348
Haemoglobin (g/dL)	11.35	1.89	11.98	1.79	-2.024	0.045
White Blood Cell Count (x 10 ³ /μL)	13.21	8.303	14.62	9.60	-0.927	0.356
Platelets	258.07	120.43	279.85	130.27	-1.026	0.307
Neutrophils (%)	77.89	10.26	82.90	11.96	-2.647	0.009
Lymphocytes (%)	16.31	10.74	11.17	8.11	3.230	0.002
Eosinophils (x 10 ³ /μL) Day1	183.9	107	157	127	1.348	0.18
Eosinophils (x 10 ³ /μL) Day 3	123	79.6	71.2	80.4	3.855	<0.001
Eosinophils (x 10 ³ /μL) Day 7	121	89.9	57.2	76.3	4.583	<0.001
N/L Ratio on Day 1	7.38	5.83	10.95	7.31	-3.175	0.002
N/L Ratio on Day3	6.36	4.99	11.79	10.55	-3.816	<0.001
N/L Ratio on Day 7	6.10	6.41	11.84	16.53	-2.633	0.009
Procalcitonin (ng/mL)	0.48	0.55	0.55	0.62	-0.786	0.433
CRP (mg/dl)	96.00	73.47	73.47	82.61	0.637	0.525
D-Dimer (ng/mL)	4.10	6.06	4.01	5.45	0.099	0.921

eosinophil counts on Days 3 and 7 were significantly decreased in severe COVID patients compared to non-severe patients (123 vs 71 p-values = <0.001), (121 vs 57 p-values = <0.001) respectively. According to Table 3, more patients in the severe group (87.1% vs. 12.9% p value=0.001) required non-invasive ventilation than in the non-severe group (12.9%).

Table III: Outcome of COVID-19 patients concerning Disease Severity

Disease severity	Non-severe n =66		Severe n =75		Pearson Chi-Square
Non-Invasive Ventilation					18.347 <0.001
Yes	4	12.9%	27	87.1%	
No	62	56.4%	48	43.6%	
Outcome					3.927 0.048
Discharge or Referred to ICU	64	49.2%	66	50.8%	
Death	2	18.2%	9	81.8%	

Figure I: ROC curve showing sensitivity in Eosinopenia





Figure II: ROC curve showing sensitivity in NLR ratio



DISCUSSION

The upper limit of the normal range for eosinophil is 350 cells/mm³ blood, which is commonly between 1% and 3% of peripheral blood leucocytes¹⁴. The sequestration of eosinophils in the peripheral tissues triggered by chemotactic factors generated in response to inflammation and mediated by the adrenal axis are a few of the multifactorial causes of eosinopenia in sepsis¹⁵. According to Cortés et al., eosinopenia may be linked to adverse illness outcomes in COVID-19 infection, and it was more frequently seen in patients who had died during the hospital course than in those who had recovered¹⁶. Similarly, Roca et al. and others also supported that persistent eosinopenia after admission was associated with high disease severity¹⁷⁻¹⁹. However, our results are against Soni et al., who found no prognostically significant relation between eosinopenia and COVID-19 pneumonia²⁰. The results of our study showed that the two groups of patients had a significant difference in symptoms at presentation, NLR, and Eosinophil count. In our study, increasing age was an essential factor associated with poor outcomes, as reported in other studies^{21,22}. Our study's median absolute eosinophil count on days 3 and 7 in severe COVID pneumonia patients was 71 and 57, respectively. In our study, there was a link between persistent eosinopenia and poor outcomes, including in-hospital death. It has been hypothesized that continuous eosinopenia and increased NLR after admission is associated with poor rates of recovery^{17,22,23}. Eosinophil count patterns across the course of the disease in our study between the non-severe and severe groups revealed a substantial difference; similarly, in our research, it is also observed that persistent eosinopenia, i.e. on days 3 and 7 were associated with worse outcomes and death. The area under the eosinopenia ROC curve is 0.71 and 0.69 on days 7 and 3, respectively. The eosinopenia on day 7 is fair in predicting severe COVID-19 pneumonia compared with NLR, which was poor in predicting severe COVID in our study. Eosinophil cell count (cutoff of 100 cells/mm³) revealed a sensitivity of 75% for severe COVID-19 pneumonia using the area under the receiver operating characteristics (ROC) curve **Figure I**. These findings lead us to believe that persistent eosinopenia can serve as a warning sign for a severe COVID-19 infection and give us a solid scientific foundation for the early detection of severe COVID-19 pneumonia. Additionally, it can help us to anticipate COVID-related ARDS earlier and, thus, timely escalation of therapy. The limitation of our study is that it's a single-centre study conducted at a high-dependency unit. More studies at multiple centres should be conducted to establish eosinopenia's role and elevated NLR in COVID-19 infection.

CONCLUSION

Eosinopenia and elevated NLR were found with increased frequency in patients with severe covid pneumonia; however, persistent eosinopenia of <100cells/mm³ after admission was a better marker than elevated NLR in predicting COVID-19 infection severity and low rates of recovery. Additional research is required to determine this marker's optimal cutoff values and assess the relationship between the severity of COVID-19 pneumonia and the advancement of eosinopenia.

Ethical permission: Dow University of Health Sciences IRB letter No. IRB-2254/DUHS/Approval/2021/607.

Conflict of interest: The authors declare no conflict of interest.

Funding: This research did not receive specific funding from any financially supporting body.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publically.

AUTHOR'S CONTRIBUTION

Kashif SM: Conception, design and final approval of study
Sunder WH: Analysis and interpretation of data
Qadeer R: Conception and provision of patients
Kumar D: Drafting of article, critical revision of article
Anum G: Drafting of article
Kumar R: Critical revision of the article

REFERENCES

- Wang X, Zhang G, Jiang X, Zhu H, Lu Z, Xu L. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. *Atherosclerosis*. 2014; 234(1): 206-213. doi:10.1016/j.atherosclerosis.2014.03.003
- Eslamijouybari M, Heydari K, Maleki I, Moosazadeh M, Hedayatizadeh-Omran A, Vahedi L et al. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19 Patients and Control Group and Relationship with Disease Prognosis. *Caspian J Intern Med*. 2020 Fall; 11(Suppl 1): 531-535. doi:10.22088/cjim.11.0.531.
- Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? *BMC Res Notes*. 2017; 10: 12. Published Online 2017 Jan 3. doi:10.1186/s13104-016-2335-5
- Gil H, Magy N, Mauny F, Dupond JL. Value of eosinopenia in inflammatory disorders: an "old" marker revisited. *Rev Med Interne*. 2003; 24(7): 431-435. doi:10.1016/s0248-8663(03)00138-3.
- Liu J, Li H, Luo M, Liu J, Wu L, Lin X et al. Lymphopenia predicted illness severity and recovery in patients with COVID-19: A single-centre, retrospective study. *PLoS One*. 2020; 15(11): e0241659. doi:10.1371/journal.pone.0241659.
- Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect*. 2020; 81(1): e6-e12. doi:10.1016/j.jinf.2020.04.002.
- Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020; 75(7): 1730-1741. doi:10.1111/all.14238. Epub 2020 Feb 27.
- Outh R, Boutin C, Gueudet P, Suzuki M, Saada M, Aumaître H. Eosinopenia <100/ μ L as a marker of active COVID-19: An observational prospective study. *J Microbiol Immunol Infect*. 2021; 54(1): 61-68. doi: 10.1016/j.jmii.2020.12.005.
- Terradas R, Grau S, Blanch J, Riu M, Saballs P, Castells X et al. Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study. *PLoS One*. 2012; 7(8): e42860. doi: 10.1371/journal.pone.0042860. Epub 2012 Aug 9.
- Holub K, Biete A. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. *BMC Cancer*. 2018 Dec 22; 18(1): 1280. doi: 10.1186/s12885-018-5131-x.
- Branicka O, Rogala B, Glück J. Eosinophil/Neutrophil/Platelet-to-Lymphocyte Ratios in Various Types of Immediate Hypersensitivity to NSAIDs: A Preliminary Study. *Int Arch Allergy Immunol*. 2020; 181(10): 774-782. doi: 10.1159/000509116. Epub 2020 Aug 19.
- Anurag A, Jha PK, Kumar A. Differential white blood cell count in the COVID-19: A cross-sectional study of 148 patients. *Diabetes Metab Syndr*. 2020; 14(6): 2099-2102. doi:10.1016/j.dsx.2020.10.029. Epub 2020 Nov 2.
- Georgakopoulou VE, Garpis N, Damaskos C, Valsami S, Dimitroulis D, Diamantis E et al. The impact of peripheral eosinophil counts and eosinophil to lymphocyte ratio (ELR) in the clinical course of COVID-19 patients: A retrospective study. *In Vivo*. 2021; 35(1): 641-8. doi: 10.21873/in vivo.12303.
- Rothenberg ME. Eosinophilia. *N Engl J Med*. 1998 May 28;338(22):1592-600. doi: 10.1056/NEJM199805283382206.
- Bass DA, Gonwa TA, Szejda P, Cousart MS, DeChatelet LR, McCall CE. Eosinopenia of acute infection: production of eosinopenia by chemotactic factors of acute inflammation. *J Clin Invest*. 1980 Jun 1; 65(6): 1265-71.
- Cortés-Vieyra R, Gutiérrez-Castellanos S, Álvarez-Aguilar C, Baizabal-Aguirre VM, Nuñez-Anita RE, Rocha-López AG et al. Behavior of eosinophil

- counts in recovered and deceased COVID-19 patients over the course of the disease. *Viruses*. 2021 Aug 24; 13(9): 1675. doi: 10.3390/v13091675.
17. Roca E, Ventura L, Zattra CM, Lombardi C. EOSINOPENIA: an early, effective and relevant COVID-19 biomarker?. *QJM*. 2021; 114(1): 68-69. doi: 10.1093/qjmed/hcaa259.
 18. Rafai WA, Ussaid A, Riaz B, Baig FA, Anwar S, Masood A et al. Correlation of hematological findings with severity of COVID-19. *Med Res Arch*. 2022; 10(5): 1-13. doi: 10.18103/mra.v10i5.2740.
 19. Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH. Eosinopenia and COVID-19. *J AM Osteopath Assoc*. 2020; 120(8): 504-8.
 20. Soni M. Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection. *Int J Lab Hematol*. 2021 Jul; 43 (Suppl 1): 137-41. doi: 10.1111/ijlh.13425. Epub 2020 Dec 8.
 21. Henry BM, De Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med*. 2020; 58(7): 1021-8. doi: 10.1515/cclm-2020-0369.
 22. Waris A, Din M, Khalid A, Abbas Lail R, Shaheen A, Khan N et al. Evaluation of hematological parameters as an indicator of disease severity in Covid-19 patients: Pakistan's experience. *J Clin Lab Anal*. 2021 Jun; 35(6): e23809. doi: 10.1002/jcla.23809. Epub 2021 May 24.
 23. Jemaa AB, Salhi N, Othmen MB, Ali HB, Guissouma J, Ghadhoun H et al. Evaluation of individual and combined NLR, LMR and CLR ratio for prognosis disease severity and outcomes in patients with COVID-19. *Int Immunopharmacol*. 2022 Aug; 109: 108781. doi: 10.1016/j.intimp.2022.108781. Epub 2022 Apr 19.

